James Ryan Mark

879 total citations
35 papers, 163 citations indexed

About

James Ryan Mark is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, James Ryan Mark has authored 35 papers receiving a total of 163 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Surgery, 11 papers in Pulmonary and Respiratory Medicine and 5 papers in Oncology. Recurrent topics in James Ryan Mark's work include Bladder and Urothelial Cancer Treatments (13 papers), Urinary and Genital Oncology Studies (7 papers) and Renal cell carcinoma treatment (6 papers). James Ryan Mark is often cited by papers focused on Bladder and Urothelial Cancer Treatments (13 papers), Urinary and Genital Oncology Studies (7 papers) and Renal cell carcinoma treatment (6 papers). James Ryan Mark collaborates with scholars based in United States, Georgia and Canada. James Ryan Mark's co-authors include Patrick J. Shenot, Francisco Gelpi‐Hammerschmidt, Costas D. Lallas, Edouard J. Trabulsi, J.T. HARVEY, Mary I. O’Connor, Eric M. Horwitz, Elizabeth R. Plimack, Lambros Stamatakis and Pooja Ghatalia and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Journal of Urology.

In The Last Decade

James Ryan Mark

33 papers receiving 159 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
James Ryan Mark United States 7 105 44 31 24 16 35 163
Igor Duquesne France 10 125 1.2× 66 1.5× 46 1.5× 59 2.5× 6 0.4× 38 208
Alessandro Raffaele Italy 10 137 1.3× 34 0.8× 31 1.0× 24 1.0× 6 0.4× 32 197
Marisa Adelman United States 8 101 1.0× 33 0.8× 62 2.0× 14 0.6× 8 0.5× 17 285
M. Andou Japan 11 98 0.9× 19 0.4× 22 0.7× 32 1.3× 8 0.5× 50 326
Stephen E. Zimberg United States 10 167 1.6× 13 0.3× 21 0.7× 13 0.5× 15 0.9× 25 410
Camilo Giedelman United States 7 83 0.8× 104 2.4× 27 0.9× 7 0.3× 11 0.7× 17 160
Demytra Mitsis United States 7 273 2.6× 15 0.3× 17 0.5× 27 1.1× 21 1.3× 10 387
Tomasz Szopiński Poland 8 144 1.4× 60 1.4× 33 1.1× 34 1.4× 5 0.3× 34 258
Syed Muhammad Ali Qatar 6 115 1.1× 21 0.5× 4 0.1× 19 0.8× 14 0.9× 48 172
Mirko Dolci Switzerland 9 49 0.5× 48 1.1× 7 0.2× 39 1.6× 9 0.6× 19 182

Countries citing papers authored by James Ryan Mark

Since Specialization
Citations

This map shows the geographic impact of James Ryan Mark's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Ryan Mark with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Ryan Mark more than expected).

Fields of papers citing papers by James Ryan Mark

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Ryan Mark. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Ryan Mark. The network helps show where James Ryan Mark may publish in the future.

Co-authorship network of co-authors of James Ryan Mark

This figure shows the co-authorship network connecting the top 25 collaborators of James Ryan Mark. A scholar is included among the top collaborators of James Ryan Mark based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Ryan Mark. James Ryan Mark is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ghatalia, Pooja, Eric A. Ross, Matthew R. Zibelman, et al.. (2025). A phase 2 trial of risk enabled therapy after neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer (RETAIN-2).. Journal of Clinical Oncology. 43(5_suppl). 815–815. 2 indexed citations
2.
3.
Mann, Mark, et al.. (2024). Complications and Influential Perioperative Factors Associated with SpaceOAR Hydrogel Placement. Advances in Urology. 2024(1). 3439727–3439727. 3 indexed citations
4.
5.
Geynisman, Daniel M., Philip H. Abbosh, Eric A. Ross, et al.. (2024). Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1). Journal of Clinical Oncology. 43(9). 1113–1122. 9 indexed citations
6.
Shah, Mihir, Yash Shah, Saum Ghodoussipour, et al.. (2024). A Narrative Review on Robotic Surgery as Treatment for Renal Cell Carcinoma with Inferior Vena Cava Thrombus. Journal of Clinical Medicine. 13(5). 1308–1308. 2 indexed citations
7.
Mark, James Ryan, Costas D. Lallas, Edouard J. Trabulsi, et al.. (2024). Risk of Secondary Malignancies After Pelvic Radiation: A Population-based Analysis. European Urology Open Science. 63. 52–61. 4 indexed citations
8.
Hamilton‐Reeves, Jill, Joseph M. Unger, Jeffrey M. Holzbeierlein, et al.. (2024). Effects of immune-enhancing nutrition on radical cystectomy outcomes: Primary results from the randomized phase III double-blind clinical trial (S1600).. Journal of Clinical Oncology. 42(16_suppl). 4501–4501. 3 indexed citations
9.
Chandrasekar, Thenappan, Vasil Mico, Yash Shah, et al.. (2023). Multiparametric MRI is not sufficient for prostate cancer staging: A single institutional experience validated by a multi-institutional regional collaborative. Urologic Oncology Seminars and Original Investigations. 41(8). 355.e1–355.e8. 6 indexed citations
10.
Shah, Yash, James Ryan Mark, Mihir Shah, et al.. (2023). Risk analysis of open vs. robotic assisted radical cystectomy.. Journal of Clinical Oncology. 41(6_suppl). 576–576. 1 indexed citations
11.
Geynisman, Daniel M., Philip H. Abbosh, Eric A. Ross, et al.. (2023). A phase II trial of risk-enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer (RETAIN).. Journal of Clinical Oncology. 41(6_suppl). 438–438. 23 indexed citations
12.
Chandrasekar, Thenappan, Andrew A. Gomella, Corinne E. Wessner, et al.. (2022). Volumetric Quantitative Contrast-enhanced Ultrasonography Evaluation of Complex Renal Cysts: An Adjunctive Metric to the Bosniak Classification System to Predict Malignancy. European Urology Focus. 9(2). 336–344. 5 indexed citations
13.
Gomella, Patrick T., James Ryan Mark, Veda N. Giri, William Kevin Kelly, & Leonard G. Gomella. (2022). Guidelines on Germline Testing for Urologic Tumor Syndromes. European Urology Focus. 8(3). 670–673. 3 indexed citations
14.
Mark, James Ryan, et al.. (2022). Risk of secondary malignancies after pelvic radiation: A population-based analysis.. Journal of Clinical Oncology. 40(6_suppl). 478–478. 1 indexed citations
15.
Mark, James Ryan, Carey McDougall, & Veda N. Giri. (2021). Genetic Testing Guidelines and Education of Health Care Providers Involved in Prostate Cancer Care. Urologic Clinics of North America. 48(3). 311–322. 3 indexed citations
16.
Chandrasekar, Thenappan, Hanan Goldberg, James Ryan Mark, et al.. (2021). Outcomes of Active Surveillance for Men With Intermediate Risk Prostate Cancer: A Population-Based Analysis. Urology. 155. 101–109. 2 indexed citations
17.
Geynisman, Daniel M., Philip H. Abbosh, Eric A. Ross, et al.. (2021). A phase II trial of risk enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer (RETAIN BLADDER): Interim analysis.. Journal of Clinical Oncology. 39(6_suppl). 397–397. 19 indexed citations
18.
Chandrasekar, Thenappan, Joon Yau Leong, Misung Yi, et al.. (2020). Simple frameshifts in minimally invasive surgery postoperative pain management significantly reduce opiate prescriptions.. PubMed. 27(3). 10250–10256. 1 indexed citations
19.
Chandrasekar, Thenappan, Joon Yau Leong, Seth Teplitsky, et al.. (2020). Setting the Standards: Examining Research Productivity Among Academic Urologists in the USA and Canada in 2019. European Urology Focus. 7(2). 489–496. 3 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Igor Duquesne Breakdown of academic impact, for papers by Alessandro Raffaele Breakdown of academic impact, for papers by Marisa Adelman Breakdown of academic impact, for papers by M. Andou Breakdown of academic impact, for papers by Stephen E. Zimberg Breakdown of academic impact, for papers by Camilo Giedelman Breakdown of academic impact, for papers by Demytra Mitsis Breakdown of academic impact, for papers by Tomasz Szopiński Breakdown of academic impact, for papers by Syed Muhammad Ali Breakdown of academic impact, for papers by Mirko Dolci
Rankless by CCL
2026